DBV Technologies

Epidemiological studies suggest that over half of Americans are sensitive to at least one allergen. Environmental and lifestyle changes, urbanization, pollution, dietary changes, development of sanitation standards and decrease in chronic bacterial infections all are assumed to be factors promoting the rapid increase in prevalence of allergy throughout the developed world. Approximately 3% to 5% of Americans suffer from food allergies with a number of recent studies suggesting that approximately 8% of children have some type of food allergy. Recent studies suggest that patients with food allergies are especially at risk of experiencing significant disruption in their daily lives. Recent scientific studies suggest that treating allergies early in life could prevent disease progression or the development of polyallergies, however, no approved treatments currently exist for young allergic children.
Type
Public
HQ
Montrouge, FR
Founded
2002
Employees
113 (est)
DBV Technologies was founded in 2002 and is headquartered in Montrouge, FR

Key People at DBV Technologies

Bertrand Dupont

Bertrand Dupont

CTO
David Schilansky

David Schilansky

CFO
Charles Ruban

Charles Ruban

CDO
Pierre-Henri Benhamou

Pierre-Henri Benhamou

CEO & CSO

DBV Technologies Locations

Montrouge, FR
New York, US

DBV Technologies Metrics

DBV Technologies Summary

Market capitalization

€1.65 B

Closing share price

€67.7
DBV Technologies's latest market capitalization is €1.65 B.

DBV Technologies Market Value History

DBV Technologies Online Presence

DBV Technologies News

DBV Technologies Company Life

You may also be interested in